-
公开(公告)号:US20160368905A1
公开(公告)日:2016-12-22
申请号:US15141556
申请日:2016-04-28
Applicant: AbbVie Inc.
Inventor: David A. Betebenner , John K. Pratt , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Douglas K. Hutchinson , Warren M. Kati , Allan C. Krueger , Kenton L. Longenecker , Clarence J. Maring , John T. Randolph , Todd W. Rockway , Michael D. Tufano , Rolf Wagner , Dachun Liu
IPC: C07D409/10 , A61K31/513 , C07D213/64 , A61K31/4418 , C07C311/08 , A61K31/18 , C07D233/72 , A61K31/4166 , A61K31/27 , C07D263/24 , A61K31/421 , C07D239/10 , C07D207/27 , A61K31/402 , C07D405/10 , C07D403/10 , A61K45/06 , A61K31/425 , C07D275/02 , C07D239/54
CPC classification number: C07D409/10 , A61K31/18 , A61K31/27 , A61K31/402 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/4418 , A61K31/503 , A61K31/513 , A61K45/06 , C07C311/08 , C07D207/27 , C07D213/64 , C07D233/32 , C07D233/72 , C07D239/10 , C07D239/54 , C07D263/22 , C07D263/24 , C07D275/02 , C07D403/10 , C07D405/10 , Y02P20/55
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本发明涉及:(a)特别是抑制HCV的化合物及其盐; (b)可用于制备这些化合物和盐的中间体; (c)包含这些化合物和盐的组合物; (d)制备这种中间体,化合物,盐和组合物的方法; (e)使用这些化合物,盐和组合物的方法; 和(f)包含这些化合物,盐和组合物的试剂盒。
-
公开(公告)号:US09249138B2
公开(公告)日:2016-02-02
申请号:US14017901
申请日:2013-09-04
Applicant: ABBVIE INC.
Inventor: David A. Degoey , Pamela L. Donner , Warren M. Kati , Charles W. Hutchins , Allan C. Krueger , John T. Randolph , Christopher E. Motter , Preethi Krishnan , Neeta C. Mistry , Tami J. Pilot-Matias , Sachin V. Patel , Xiaoyan Li , Todd N. Soltwedel , Lissa T. Nelson
IPC: C07D239/48 , C07D471/04
CPC classification number: C07D471/04 , C07D239/48
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号:US09139536B2
公开(公告)日:2015-09-22
申请号:US13838223
申请日:2013-03-15
Applicant: AbbVie Inc.
Inventor: Charles A. Flentge , Douglas K. Hutchinson , David A. Betebenner , David A. DeGoey , Pamela L. Donner , Warren M. Kati , Allan C. Krueger , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , Christopher E. Motter , John K. Pratt , John T. Randolph , Todd W. Rockway , Kent D. Stewart , Rolf Wagner , Shuang Chen , Yi Gao , Xiaochun Lou , Geoff G. Z. Zhang
IPC: A61K31/505 , C07D239/54 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K31/513 , A61K45/06
CPC classification number: C07D239/54 , A61K31/513 , A61K45/06 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K2300/00
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本发明涉及:(a)特别是抑制HCV的化合物及其盐; (b)可用于制备这些化合物和盐的中间体; (c)包含这些化合物和盐的组合物; (d)制备这种中间体,化合物,盐和组合物的方法; (e)使用这些化合物,盐和组合物的方法; 和(f)包含这些化合物,盐和组合物的试剂盒。
-
公开(公告)号:US20150065542A1
公开(公告)日:2015-03-05
申请号:US14534916
申请日:2014-11-06
Applicant: ABBVIE INC.
Inventor: Allan C. Krueger , Warren M. Kati , Clarence J. Maring , Rolf Wagner , Charles W. Hutchins
IPC: C07D403/14 , C07D409/14
CPC classification number: C07D403/14 , C07D409/14
Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.
Abstract translation: 本发明涉及抗HCV化合物,包含其的组合物以及使用该化合物治疗HCV感染的方法。
-
公开(公告)号:US20140294766A1
公开(公告)日:2014-10-02
申请号:US13838223
申请日:2013-03-15
Applicant: AbbVie Inc.
Inventor: Charles A. Flentge , Douglas K. Hutchinson , David A. Betebenner , David A. DeGoey , Pamela L. Donner , Warren M. Kati , Allan C. Krueger , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , Christopher E. Motter , John K. Pratt , John T. Randolph , Todd W. Rockway , Kent D. Stewart , Rolf Wagner , Shuang Chen , Yi Gao , Xiaochun Lou , Geoff G.Z. Zhang
IPC: C07D239/54 , A61K45/06 , A61K31/513
CPC classification number: C07D239/54 , A61K31/513 , A61K45/06 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K2300/00
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本发明涉及:(a)特别是抑制HCV的化合物及其盐; (b)可用于制备这些化合物和盐的中间体; (c)包含这些化合物和盐的组合物; (d)制备这种中间体,化合物,盐和组合物的方法; (e)使用这些化合物,盐和组合物的方法; 和(f)包含这些化合物,盐和组合物的试剂盒。
-
-
-
-